AM-679 (cannabinoid)
AM-679 is a synthetic cannabinoid that acts as a potent and selective agonist for the cannabinoid receptors. It is part of the AM series of cannabinoids developed by Alexandros Makriyannis and his team. AM-679 has been studied for its potential therapeutic applications and its effects on the endocannabinoid system.
Chemical Structure and Properties[edit]
AM-679 is chemically classified as a cannabinoid and shares structural similarities with other compounds in the AM series. The specific chemical structure of AM-679 includes a core structure that interacts with the CB1 and CB2 receptors in the endocannabinoid system.
Pharmacology[edit]
AM-679 exhibits high affinity for both the CB1 and CB2 receptors. It acts as a full agonist at these receptors, meaning it can fully activate the receptor upon binding. This activation leads to various physiological and psychoactive effects, which are characteristic of cannabinoids.
Therapeutic Potential[edit]
Research into AM-679 has indicated potential therapeutic applications, particularly in the areas of pain management, inflammation, and neurological disorders. Its ability to modulate the endocannabinoid system makes it a candidate for further investigation in these fields.
Legal Status[edit]
The legal status of AM-679 varies by country. In some jurisdictions, it may be classified as a controlled substance due to its psychoactive properties and potential for abuse. Researchers must adhere to local regulations when studying this compound.
See Also[edit]
References[edit]
 | This medical article is a stub. You can help WikiMD by expanding the page. |
